Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Public ClinicalTrials.gov record NCT07595874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.
Study identification
- NCT ID
- NCT07595874
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
- Advanced Colon Adenocarcinoma
- Advanced Colorectal Adenocarcinoma
- Advanced Rectal Adenocarcinoma
- Stage IIB Colon Cancer AJCC v8
- Stage IIB Rectal Cancer AJCC v8
- Stage IIC Colon Cancer AJCC v8
- Stage IIC Rectal Cancer AJCC v8
- Stage IIIA Colon Cancer AJCC v8
- Stage IIIA Rectal Cancer AJCC v8
- Stage IIIB Colon Cancer AJCC v8
- Stage IIIB Rectal Cancer AJCC v8
- Stage IIIC Colon Cancer AJCC v8
- Stage IIIC Rectal Cancer AJCC v8
Interventions
- Balstilimab Biological
- Biospecimen Collection Procedure
- Botensilimab Biological
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 26, 2026
- Primary completion
- May 26, 2027
- Completion
- May 26, 2027
- Last update posted
- Jun 30, 2026
2026 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 4
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CTCA at Western Regional Medical Center | Goodyear | Arizona | 85338 | Recruiting |
| City of Hope Corona | Corona | California | 92882 | Recruiting |
| City of Hope Medical Center | Duarte | California | 91010 | Recruiting |
| City of Hope Seacliff | Huntington Beach | California | 92648 | Recruiting |
| City of Hope at Irvine Lennar | Irvine | California | 92618 | Recruiting |
| City of Hope at Long Beach Elm | Long Beach | California | 90813 | Recruiting |
| City of Hope South Pasadena | South Pasadena | California | 91030 | Recruiting |
| City of Hope Upland | Upland | California | 91786 | Recruiting |
| City of Hope Atlanta Cancer Center | Newnan | Georgia | 30265 | Recruiting |
| City of Hope at Illinois Chicago Downtown | Chicago | Illinois | 60611 | Recruiting |
| City of Hope at Chicago | Zion | Illinois | 60099 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07595874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07595874 live on ClinicalTrials.gov.